Scholars Central

Search Scholars Central

Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.

Advanced searchHide advanced search

In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:

Years

1–25 of 45 articles for Crizotinib

Then save them, add them to a collection or cite them together.
  1. Conference abstract

    Microcrylaq: A new way to implement quantum computation algebraic calculations in a 3D logical space for the discovery of a novel chemical antagonist against the two crizotinib resistant ALK mutations, G1202R and F1174C

    Modern Chemistry & Applications

    kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. It has been previously been reported the first preclinical evaluation of the next-generation…

  2. Conference abstract · 20 Jul 2015

    ALK targeting by Crizotinib in pancreatic cancer

    Cancer Science & Therapy

    Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. However, studies regarding Crizotinib in pancreatic cancer have been limited. Thus, we investigated the effect…

  3. Research article · 3 May 2019

    Enantioselective Analysis of Crizotinib by Chiral LC Method

    Der Pharma Chemica · Volume 9, Issue 22

    HPLC method has been developed and validated for the Separation of enantiomers of crizotinib. The chromatographic separation was achieved on chiralcel OD-H (25 × 0.46 cm, 5 μ) column ... developed method was found to be…

  4. Conference abstract · 27 Sep 2017

    Novel ectopic signaling of MAN2A1-FER fusion protein

    presence of MAN2A1-FER increased the sensitivity of human cancers to FER kinase inhibitor crizotinib or EGFR kinase inhibitor canertinib. Hydrodynamic tail-vein injection of MAN2A1-FER gene resulted

  5. Research article · 31 Jan 2022

    Structure Based Virtual Screening of Selected Phytochemicals aganist C1156y Mutant Anaplastic Lymphoma Kinase (ALK) using Molecular Docking and Admet Prediction

    Journal of Drug and Alcohol Research · Volume 11, Issue 1

    activity leading to cell proliferation and tumourigenesis causing Non-Small Cell Lung Cancer (NSCLC). Crizotinib emerged as a first-generation ALK inhibitor; however it developed resistance within a year ... patients…

  6. Conference abstract · 12 Sep 2016

    Key success factors implementing precision medicine

    approved a number of so called targeted therapies primarily in the cancer space: crizotinib, vemaurafinib, dabrafenib and treminib – each have been approved for use in patients with a particular tumor

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels